GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AngioLab Inc (XKRX:251280) » Definitions » Total Stockholders Equity

AngioLab (XKRX:251280) Total Stockholders Equity : ₩1,968.6 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is AngioLab Total Stockholders Equity?

AngioLab's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₩1,968.6 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. AngioLab's Book Value per Share for the quarter that ended in Dec. 2023 was ₩477.33. The ratio of a company's debt over equity can be used to measure how leveraged this company is. AngioLab's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.05.

AngioLab Total Stockholders Equity Historical Data

The historical data trend for AngioLab's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioLab Total Stockholders Equity Chart

AngioLab Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Stockholders Equity
Get a 7-Day Free Trial -14,372.90 2,704.30 6,243.51 4,260.99 1,968.55

AngioLab Semi-Annual Data
Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Stockholders Equity Get a 7-Day Free Trial -14,372.90 2,704.30 6,243.51 4,260.99 1,968.55

AngioLab  (XKRX:251280) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

AngioLab's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(1968.552-583.916)/2.90079
=477.33

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

AngioLab's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(60.806 + 43.969) / 1968.552
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AngioLab Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of AngioLab's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

AngioLab (XKRX:251280) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AngioLab Inc (XKRX:251280) » Definitions » Total Stockholders Equity
Comparable Companies
XKRX:072520 XKRX:446440 XKRX:215380 XKRX:322970 XKRX:283100 XKRX:950220 XKRX:343090 XKRX:179530 XKRX:388610 XKRX:208340 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
65 Techno 3ro, Suite 159, Hanshin S Mecca, Yuseong-gu, Doejeon, CHN
Website
http://www.angiolab.co.kr
AngioLab Inc is a biotechnology company. It develops products based on angiogenesis inhibitors. It discovers, develops, and markets anti-angiogenic candidates to inhibit the abnormal growth of new blood vessel.

AngioLab (XKRX:251280) Headlines

No Headlines